The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
I am a Molecular Biologist who has built up a large set of transgenic animal models based around the NPY system to use them in an integrated physiology approach to investigate important regulatory mechanisms in the interaction of the brain with peripheral
I am a molecular-cell biologist investigating the genetic control of lymphocyte differentiation. I study the mechanisms of action of transcription factors expressed specifically in B cells that regulate B lymphocyte specialisation and function, that determine the ability of mature B cells to respond to signals from other cells or from invading pathogens, and that enable the differentiation of antibody-secreting cells, the effectors of the B cell lineage. I lead the commercialisation efforts of o ....I am a molecular-cell biologist investigating the genetic control of lymphocyte differentiation. I study the mechanisms of action of transcription factors expressed specifically in B cells that regulate B lymphocyte specialisation and function, that determine the ability of mature B cells to respond to signals from other cells or from invading pathogens, and that enable the differentiation of antibody-secreting cells, the effectors of the B cell lineage. I lead the commercialisation efforts of our research Program.Read moreRead less
Too little or too much of the essential element iron is the cause of some of the most common disorders affecting humans. These include iron overload, anaemia, and anaemia of chronic disease. This project examines the genes and the roles they play in regulating iron levels in the body, and the consequences to the individuals when they are mutated. Ultimately I intend to develop therapeutics and diagnostics which will help early diagnosis and effective treatment of these disorders.
Epilepsy is a very common and serious brain disorder. Epilepsy often includes other disabilities, reduction in quality of life and is associated with increased risk of early death. 30% of people with epilepsy are unable to gain control of their seizures with currently available medications. The genetic causes of the large majority of epilepsy cases have not yet been found. This project aims to identify new genetic causes of epilepsy and its related disorders.
I aim to decipher the role of heritable, genetic DNA variation in human neurological disease. I will use next generation genomics technologies together with sophisticated cellular models to address the important questions of the biology of epilepsy and intellectual disability in particular. I aim to develop a treatment for a specific type of epilepsy, which affects only girls from the age of 6 months. My ultimate goal is to improve the life of the patients and their relatives.
The genetic material is packaged in the cell nucleus with histone proteins. Modifications of histones determine if a particular area of the genome is active or repressed. We are investigating the roles of a family of histone modifying proteins, the MYST proteins. Mutations in these proteins cause intellectual disability and cancer. The research program will provide knowledge that may become the basis for the development of drugs for the treatment of cancer and neurodegenerative disorders.
High-Throughout Identification And Targeting Of New Breast Cancer Genes.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Recent studies have identified DNA sequence variations within the human genome that are associated with an increased risk or can influence the outcome of breast cancer. This research program will identify the key genes affecting cancer development and assess their contribution to cancer growth. I will then use this knowledge to assess their suitability for drug development. Understanding how our DNA contributes to breast cancer will provide new avenues for prevention or treatment.
Cancer is a genetic disease – it occurs because of genetic changes in the body that change how a cell grows, and because it occurs more often in people who have an inherited predisposition to cancer. My aim is to uncover more of the genetic events that give rise to cancer, particularly of the breast, ovary and stomach, so that we can identify people at high risk, and advice them accordingly, and also so that we can devise better treatments directed at particular genetic alterations.
Translation Of Genetic, Genomic And Transcriptomic Discoveries Into Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
This project will progress studies on genes affecting common diseases to clinical application. Specifically, I aim to (1) establish the basis for the association of the identified MS risk factors with MS susceptibility; (2) establish if the three MS blood immune types we have identified, which are tagged by MS susceptibility genes, and altered by MS therapy, predict clinical response to therapy; and (3) determine the effect of host genetic variation in response to therapy for HCV, HIV and flu.
The goal of this research is to improve outcomes for people at risk of becoming blind or visually impaired. The focus is on those who require a corneal transplant, or who suffer from inflammatory eye disease or painful disease of the ocular surface, on neonates with retinopathy of prematurity, or those with the eye disease, keratoconus. We will investigate new treatment options for eye diseases and will examine the evidence for the success of surgical and other therapeutic interventions.